Accent Capital Management LLC Has $116,000 Holdings in Johnson & Johnson (NYSE:JNJ)

Accent Capital Management LLC reduced its holdings in Johnson & Johnson (NYSE:JNJ) by 48.9% in the 4th quarter, Holdings Channel reports. The fund owned 801 shares of the company’s stock after selling 768 shares during the quarter. Accent Capital Management LLC’s holdings in Johnson & Johnson were worth $116,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Norges Bank bought a new stake in Johnson & Johnson in the 4th quarter valued at $4,390,037,000. Raymond James Financial Inc. bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $1,339,878,000. Janus Henderson Group PLC grew its holdings in shares of Johnson & Johnson by 228.1% during the third quarter. Janus Henderson Group PLC now owns 3,389,361 shares of the company’s stock worth $549,223,000 after buying an additional 2,356,359 shares in the last quarter. Vanguard Group Inc. raised its position in Johnson & Johnson by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company’s stock valued at $33,666,460,000 after buying an additional 1,772,706 shares during the last quarter. Finally, Franklin Resources Inc. boosted its position in Johnson & Johnson by 11.4% during the 3rd quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company’s stock worth $2,721,355,000 after acquiring an additional 1,729,281 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling

In other news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on JNJ. Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 19th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Leerink Partners lowered their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Bank of America raised their price target on Johnson & Johnson from $159.00 to $171.00 and gave the company a “neutral” rating in a research note on Wednesday, March 5th. Finally, Stifel Nicolaus cut their price objective on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $171.33.

Johnson & Johnson Trading Up 0.3 %

Shares of Johnson & Johnson stock opened at $163.63 on Friday. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The stock has a market cap of $394.32 billion, a PE ratio of 24.61, a PEG ratio of 2.56 and a beta of 0.47. The firm has a 50-day moving average of $158.68 and a 200-day moving average of $156.21. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period last year, the firm earned $2.29 earnings per share. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were issued a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.03%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.